AU2016290197B2 - Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions - Google Patents

Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions Download PDF

Info

Publication number
AU2016290197B2
AU2016290197B2 AU2016290197A AU2016290197A AU2016290197B2 AU 2016290197 B2 AU2016290197 B2 AU 2016290197B2 AU 2016290197 A AU2016290197 A AU 2016290197A AU 2016290197 A AU2016290197 A AU 2016290197A AU 2016290197 B2 AU2016290197 B2 AU 2016290197B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
ocular
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016290197A
Other languages
English (en)
Other versions
AU2016290197A1 (en
Inventor
Achim Hans-Peter Krauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axerovision Inc
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of AU2016290197A1 publication Critical patent/AU2016290197A1/en
Application granted granted Critical
Publication of AU2016290197B2 publication Critical patent/AU2016290197B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016290197A 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions Ceased AU2016290197B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (2)

Publication Number Publication Date
AU2016290197A1 AU2016290197A1 (en) 2018-01-04
AU2016290197B2 true AU2016290197B2 (en) 2021-07-22

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016290197A Ceased AU2016290197B2 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Country Status (21)

Country Link
US (3) US10413535B2 (https=)
EP (1) EP3319639B1 (https=)
JP (2) JP6752276B2 (https=)
KR (2) KR20220062688A (https=)
CN (1) CN107921136A (https=)
AU (1) AU2016290197B2 (https=)
BR (1) BR112018000112A2 (https=)
CA (1) CA2989522C (https=)
CL (1) CL2018000057A1 (https=)
ES (1) ES2835274T3 (https=)
HK (1) HK1247120A1 (https=)
IL (2) IL256770B (https=)
MA (2) MA42016A1 (https=)
MX (1) MX385229B (https=)
MY (1) MY187552A (https=)
PL (1) PL3319639T3 (https=)
RU (1) RU2018103940A (https=)
TN (1) TN2017000538A1 (https=)
UA (1) UA123728C2 (https=)
WO (1) WO2017006272A1 (https=)
ZA (1) ZA201708601B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
EP3624773A4 (en) * 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
MX2022001062A (es) * 2019-07-26 2022-02-14 Allegro Pharmaceuticals Llc Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20230110514A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation
US6867192B1 (en) * 1998-12-18 2005-03-15 Duncan Robert Armour Compounds useful in the treatment of inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867192B1 (en) * 1998-12-18 2005-03-15 Duncan Robert Armour Compounds useful in the treatment of inflammatory diseases
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, "An inhaled VLA-4 antagonist", EXPERT OPINION ON THERAPEUTIC PATENTS., GB, (2002-05-01), vol. 12, no. 5, doi:10.1517/13543776.12.5.755, ISSN 1354-3776, pages 755 - 757 *
Clara Andonian, IOVS, (2015-06-01), pages 1 - 2, URL: http://iovs.arvojournals.org/article.aspx?articleid=2334394, (2016-08-25) *
KRAUSS A. H. ET AL, "Effects of a novel integrin antagonist, GW559090, in an experimental dry eye model (Program number 2472)", IOVS, & ARVO, 2015, vol. 56, no. 7 *

Also Published As

Publication number Publication date
UA123728C2 (uk) 2021-05-26
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17
RU2018103940A3 (https=) 2019-09-03
CA2989522C (en) 2022-10-18
IL256770A (en) 2018-03-29
KR20220062688A (ko) 2022-05-17
KR20180041122A (ko) 2018-04-23
ES2835274T3 (es) 2021-06-22
IL280827A (en) 2021-04-29
AU2016290197A1 (en) 2018-01-04
MX2017017163A (es) 2018-08-09
WO2017006272A1 (en) 2017-01-12
CA2989522A1 (en) 2017-01-12
US20200000786A1 (en) 2020-01-02
JP2018521126A (ja) 2018-08-02
JP2020121985A (ja) 2020-08-13
PL3319639T3 (pl) 2021-03-08
CN107921136A (zh) 2018-04-17
ZA201708601B (en) 2019-05-29
TN2017000538A1 (en) 2019-04-12
US20200405703A1 (en) 2020-12-31
JP6752276B2 (ja) 2020-09-09
EP3319639A1 (en) 2018-05-16
KR102440162B1 (ko) 2022-09-02
MY187552A (en) 2021-09-29
RU2018103940A (ru) 2019-08-08
MX385229B (es) 2025-03-14
BR112018000112A2 (pt) 2018-09-04
IL256770B (en) 2021-02-28
MA42016A1 (fr) 2018-03-30
US20180200240A1 (en) 2018-07-19
CL2018000057A1 (es) 2018-06-22
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
HK1247120A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
US10751334B2 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
EP3525799B1 (en) Method for establishing, restoring, and preserving homeostasis of the ocular surface
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
KR20210093274A (ko) 자가항체-매개 안 질환의 치료 및 진단
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2021260430A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US20200138806A1 (en) Nutlin-3a for Treatment of Proliferative Vitreoretinopathy
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
CN107106566A (zh) 晶状体硬化抑制剂
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired